CLINICAL TRIALS PROFILE FOR TL-895

Clinical Trials for TL-895

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02825836 ↗	Phase I/II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma	Recruiting	Merck KGaA	Phase 1/Phase 2	The purpose of this research study is to determine the safety and tolerability of TL-895. There are 2 parts of this study. Part 1 tested increasing doses of TL-895 to identify the recommended safe dose for participants with relapsed/refractory (R/R) B cell malignancies who failed at least 1 but no more than 3 prior therapies. Part 1 of this study is no longer enrolling participants. Part 2 of this study will test different doses of TL-895 in participants with R/R CLL or SLL who have failed at least 1 prior therapy. Part 2 of this study is randomized (like the flip of a coin) to receive a specific treatment dose. If someone participates in Part 2, the dose they receive will be either 100mg twice a day or 150mg twice a day. Every participant in this study will receive TL-895.
NCT02825836 ↗	Phase I/II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma	Recruiting	EMD Serono Research & Development Institute, Inc.	Phase 1/Phase 2	The purpose of this research study is to determine the safety and tolerability of TL-895. There are 2 parts of this study. Part 1 tested increasing doses of TL-895 to identify the recommended safe dose for participants with relapsed/refractory (R/R) B cell malignancies who failed at least 1 but no more than 3 prior therapies. Part 1 of this study is no longer enrolling participants. Part 2 of this study will test different doses of TL-895 in participants with R/R CLL or SLL who have failed at least 1 prior therapy. Part 2 of this study is randomized (like the flip of a coin) to receive a specific treatment dose. If someone participates in Part 2, the dose they receive will be either 100mg twice a day or 150mg twice a day. Every participant in this study will receive TL-895.
NCT02825836 ↗	Phase I/II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma	Recruiting	Telios Pharma, Inc.	Phase 1/Phase 2	The purpose of this research study is to determine the safety and tolerability of TL-895. There are 2 parts of this study. Part 1 tested increasing doses of TL-895 to identify the recommended safe dose for participants with relapsed/refractory (R/R) B cell malignancies who failed at least 1 but no more than 3 prior therapies. Part 1 of this study is no longer enrolling participants. Part 2 of this study will test different doses of TL-895 in participants with R/R CLL or SLL who have failed at least 1 prior therapy. Part 2 of this study is randomized (like the flip of a coin) to receive a specific treatment dose. If someone participates in Part 2, the dose they receive will be either 100mg twice a day or 150mg twice a day. Every participant in this study will receive TL-895.
NCT04419623 ↗	A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer	Completed	Telios Pharma, Inc.	Phase 1	This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles. Up to 3 dose levels will be evaluated. Only Phase 1 of the study was enrolled and the study did not proceed into Phase 2.
NCT04640532 ↗	KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF	Recruiting	Telios Pharma, Inc.	Phase 1/Phase 2	This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
NCT04640532 ↗	KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF	Recruiting	Kartos Therapeutics, Inc.	Phase 1/Phase 2	This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

Clinical Trial Conditions for TL-895

Condition Name

Condition Name
Intervention	Trials
Myelofibrosis	3
Post-ET Myelofibrosis	2
Post-PV MF	2
Primary Myelofibrosis	2

Condition MeSH

Condition MeSH
Intervention	Trials
Primary Myelofibrosis	4
Leukemia	2
Hematologic Neoplasms	1
Thrombocythemia, Essential	1

Clinical Trial Locations for TL-895

Trials by Country

Trials by Country
Location	Trials
United States	21
Poland	5
Australia	4
Germany	4
France	3

Trials by US State

Trials by US State
Location	Trials
Ohio	4
California	3
Texas	2
Michigan	2
New York	2

Clinical Trial Progress for TL-895

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	2
Phase 1/Phase 2	4
Phase 1	1

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	5
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for TL-895

Sponsor Name

Sponsor Name
Sponsor	Trials
Telios Pharma, Inc.	6
Kartos Therapeutics, Inc.	3
Merck KGaA	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	11